Saturday 25 Oct 2014

Momentum Stocks: Synergy Resources Corp (NYSEMKT:SYRG), Neurometrix Inc (NASDAQ:NURO)

Northern, WI 01/06/2013 (NISMAGAZINE) – Synergy Resources Corp (NYSEMKT:SYRG) is a domestic oil & gas-exploration and production company that is focused in the Denver-Julesburg Basin. The company is slated to hold a conference-call on Tuesday, 7 January to discuss the results for its financial Q1 that ended 30 November 2013. It plans on issuing its earnings press-release before the call.

Ed Holloway, the company’s president and Chief Executive Officer, the executive VP William Scaff, Jr., the CFO Monty Jennings and the Vice President of Operations Craig Rasmuson will host this presentation, which will be followed by a question & answer period.

About the company 

Synergy Resources Corp (NYSEMKT:SYRG) is an oil & gas operator that has operations in Colorado. It is focused on acquiring, development, the exploitation, exploration & production of oil and natural-gas properties situated in the Wattenberg-field in the D-J Basin in north-east Colorado. As of 15 November 2010, the company had 19,792 gross & 13,556 net-acres under lease; all of these are located in the D-J-Basin.

Is SYRG a solid investment at these levels? Find out here. 

Friday’s trading for Neurometrix

In Friday’s trading session there was a drop of 5.48% in Neurometrix Inc (NASDAQ:NURO). The shares opened at $2.93, which was the intraday high and closed at $2.76. Close to 0.203M shares were traded in Friday’s session and the average volume of 0.721M shares got traded over a period of 30 days. The 52-week low of Neurometrix Inc (NASDAQ:NURO) shares is $1.47 while the 52-week high stands at $4.25. The company has a market capitalization of $8.24 million.

About the company

Neurometrix Inc (NASDAQ:NURO) is a medical -device company. It is primarily focused on diagnosis and the treatment of neurological complications associated with diabetes. Neurometrix Inc (NASDAQ:NURO) is in a position to address all these unmet-needs via development of medical-devices.  It intends to advance the company’s objectives in the diabetic-neuropathy market that includes: 1-Driving Commercial-Adoption of Products for Diabetic-Neuropathy in the U.S. 

How Should Investors Trade NURO Now? Find out here. 

Disclosure:

Wallstreetanalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.

Leave a Comment